Cao, Zhu Alexander,Rong, Xianhui,inzon-Ortiz, Maria Consuelo,Longmire, Tyler,Lee, Benjamin, Hyun
申请号：
AU2015327868
公开号：
AU2015327868A1
申请日:
2015.10.02
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders. The combination may comprise an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is an inhibitor of an immune checkpoint molecule chosen from the list of inhibitors of one or more of PD-1, PD L1, PD-L2, CTLA-4, TIM-3, LAG-3, CEACAM, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR beta, or the immunomodulator is an activator of a costimulatory molecule chosen from the list of agonists of one or more of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand, and wherein (ii) the second therapeutic agent is chosen from one or more compounds as provided in Table 1, i.e. LCL 161, Rad-001 (Evrolimus), CGM097, LGH-447, LJM716 (Human monoclonal antibody), LBH589 (Panobinostat), INC424 (Ruxolitinib), BUW078 or BGJ398.
